ANVS 8-K
Annovis Bio, Inc. (ANVS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
|
|
|
(State or Other Jurisdiction | (Commission | (I.R.S. Employer |
(Address of Principal Executive Offices, and Zip Code)
(
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 | Results of Operations and Financial Condition. |
On November 12, 2025, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
| Description |
99 | ||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANNOVIS BIO, INC. | ||
Date: November 12, 2025 | By: | /s/ Maria Maccecchini |
Name: Maria Maccecchini | ||
Title: President and Chief Executive Officer | ||
Exhibit 99
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
Malvern, Pa., Nov. 12, 2025 – Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results.
"The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring all patents to our new crystal form of buntanetap while publishing compelling pharmacokinetic data that validates this milestone. The addition of a seasoned CFO strengthens our executive team precisely when it matters most. Adding to all this, we are particularly encouraged by the new biomarker findings from our Phase 2/3 study showing meaningful reductions in inflammation and neurodegeneration—powerful evidence of buntanetap's disease-modifying potential. Every element is now aligned as we move toward our data readouts—the final step before an NDA submission."
Clinical highlights – pivotal Phase 3 AD study
| ● | Annovis’ pivotal Phase 3 study in early AD (NCT06709014) remains on track, with all 84 clinical sites fully activated, recruiting, and treating participants across the U.S. |
| ● | The trial has generated robust participation, reflecting growing enthusiasm from the patient community. The screen failure rate remains within expected projections. |
| ● | The first patients have successfully completed the 6-month treatment period, a key milestone for the upcoming symptomatic readout, reinforcing steady progress toward trial completion. |
Business highlights
| ● | In October, Annovis announced encouraging biomarker results from its Phase 2/3 AD trial, showing profound reductions in key markers of neuroinflammation and neurodegeneration after treatment with buntanetap compared to placebo. The effect was observed in patients with mild and moderate stages of the disease. These findings further validate the drug’s ability to halt the toxic cascade and reinforce its potential as a potential disease-modifying therapy. |
| ● | In September, Annovis published a new peer-reviewed article highlighting the pharmacokinetics (PK) of the novel crystalline form of buntanetap and its comparison to the original form. The study, which included data from mice, dogs, |
| and humans, demonstrated a better solid-state stability of the new form while preserving its PK profile and metabolism. The article was published following the Company's announcement that all patents have been successfully transferred to the new crystal form, securing comprehensive global intellectual property protection through 2046. |
| ● | That same month, Annovis strengthened its leadership team with the appointment of Mark Guerin as CFO, a seasoned executive with a proven track record in driving financial strategy and operational excellence across biopharma organizations. |
| ● | In August, Annovis’ management attended the AAIC 2025 conference in Toronto, where it presented four scientific posters, covering the progress of its Phase 3 Alzheimer’s trial and PK characterization of buntanetap. |
Financial results
| ● | Annovis’ cash and cash equivalents totaled $15.3 million as of September 30, 2025, compared to $10.6 million as of December 31, 2024. This excludes gross proceeds from its recent $6.0 million and $3.4 million registered direct offerings in October. Annovis had 20.2 million shares of common stock outstanding as of September 30, 2025. |
| ● | Research and development expenses for the three months ending September 30, 2025, were $6.3 million compared to $2.7 million for the three months ending September 30, 2024. |
| ● | General and administrative expenses for the three months ending September 30, 2025, were $1.1 million compared to $1.7 million for the three months ending September 30, 2024. |
| ● | Annovis reported a $0.37 basic and diluted net loss per common share for the three months ending September 30, 2025, compared to a $0.97 basic and diluted net loss per common share for the three months ending September 30, 2024. |
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
(Tables to follow)
Annovis Bio Inc
Balance Sheets
|
| September 30, | | | ||
|
| 2025 |
| December 31, | ||
| | (Unaudited) | | 2024 | ||
| | | | | | |
Assets |
| |
|
| |
|
Current assets: |
| |
|
| |
|
Cash and cash equivalents | | $ | 15,286,399 | | $ | 10,551,916 |
Prepaid expenses and other current assets | |
| 1,902,562 | |
| 3,373,717 |
Total assets | | $ | 17,188,961 | | $ | 13,925,633 |
Liabilities and stockholders’ equity | |
|
| |
|
|
Current liabilities: | |
|
| |
|
|
Accounts payable | | $ | 2,112,026 | | $ | 2,305,974 |
Accrued expenses | |
| 1,621,771 | |
| 1,575,013 |
Total current liabilities | |
| 3,733,797 | |
| 3,880,987 |
Non-current liabilities: | | | | | | |
Warrant liability | | | 299,000 | | | 737,000 |
Total liabilities | |
| 4,032,797 | |
| 4,617,987 |
Commitments and contingencies | |
|
| |
|
|
Stockholders’ equity: | |
|
| |
|
|
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | | | — | | | — |
Common stock | |
| 2,019 | |
| 1,414 |
Additional paid-in capital | |
| 167,023,392 | |
| 144,155,694 |
Accumulated deficit | |
| (153,869,247) | |
| (134,849,462) |
Total stockholders’ equity | |
| 13,156,164 | |
| 9,307,646 |
Total liabilities and stockholders’ equity | | $ | 17,188,961 | | $ | 13,925,633 |
Annovis Bio Inc.
Statements of Operations
(Unaudited)
|
| Three Months Ended | | Nine Months Ended | ||||||||
| | June 30, | | September 30, | ||||||||
| | 2025 |
| 2024 |
| 2025 |
| 2024 | ||||
Operating expenses: | | |
|
| |
| | |
|
| |
|
Research and development | | $ | 6,291,171 | | $ | 2,689,561 | | $ | 16,464,609 | | $ | 14,996,868 |
General and administrative | |
| 1,143,804 | |
| 1,698,050 | |
| 3,524,500 | |
| 4,963,188 |
Total operating expenses | |
| 7,434,975 | |
| 4,387,611 | |
| 19,989,109 | |
| 19,960,056 |
Operating loss | | | (7,434,975) | | | (4,387,611) | | | (19,989,109) | | | (19,960,056) |
Other income (expense): | |
|
| |
|
| |
|
| |
|
|
Interest income | |
| 152,317 | |
| 135,430 | |
| 531,324 | |
| 205,576 |
Other financing costs | | | — | | | (524,068) | | | — | | | (1,870,128) |
Change in fair value of warrants | | | 20,000 | | | (7,862,108) | | | 438,000 | | | 2,898,892 |
Total other income, net | |
| 172,317 | |
| (8,250,746) | |
| 969,324 | |
| 1,234,340 |
Net loss | | $ | (7,262,658) | | $ | (12,638,357) | | $ | (19,019,785) | | $ | (18,725,716) |
Net loss per share | | | | | | | | | | | | |
Basic | | $ | (0.37) | | $ | (0.97) | | $ | (1.01) | | $ | (1.64) |
Diluted | | $ | (0.37) | | $ | (0.97) | | $ | (1.01) | | $ | (1.89) |
Weighted-average number of common shares used in computing net loss per share | | | | | | | | | | | | |
Basic | | | 19,685,071 | | | 12,975,808 | | | 18,876,078 | | | 11,394,729 |
Diluted | |
| 19,685,071 | |
| 12,975,808 | |
| 18,876,078 | |
| 11,431,298 |